(NASDAQ: BCYC) Bicycle Therapeutics's forecast annual revenue growth rate of 22.98% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 64.61%, and while it is forecast to beat the US market's average forecast revenue growth rate of 10.18%.
Bicycle Therapeutics's revenue in 2025 is $35,275,000.On average, 6 Wall Street analysts forecast BCYC's revenue for 2025 to be $2,500,627,098, with the lowest BCYC revenue forecast at $1,026,270,925, and the highest BCYC revenue forecast at $4,152,141,300. On average, 6 Wall Street analysts forecast BCYC's revenue for 2026 to be $2,625,122,135, with the lowest BCYC revenue forecast at $1,026,270,925, and the highest BCYC revenue forecast at $4,982,569,560.
In 2027, BCYC is forecast to generate $4,969,490,315 in revenue, with the lowest revenue forecast at $2,214,475,360 and the highest revenue forecast at $9,668,261,017.